- Policy
- Donepezil patch is cheaper than 99 existing formulations
- by Lee, Tak-Sun Jul 22, 2022 05:53am
- Donepezil, a dementia treatment that has attracted attention for its convenience of administration, has been listed at a lower price than existing drugs, indicating that it has price competitiveness. 87.5mg patch, which replaces the existing 5mg tablet, costs 8,310 won per week, which is about 6,000 won cheaper than the highest price of t
- Policy
- Drug e-labeling and abolition of PMS reexaminations...
- by Lee, Hye-Kyung Jul 22, 2022 05:53am
- The Ministry of Food and Drug Safety announced that it will refrain from making a unilateral announcement of regulations, and Suk-Yeol Yoon’s government announced that it would reform regulations by listening to the opinions of the industry. As part of such efforts, the MFDS had conducted 7 internal discussions since Yoon’s inauguration to
- Policy
- Billions of won in losses if applied retroactively
- by Lee, Tak-Sun Jul 22, 2022 05:53am
- The pharmaceutical industry is complaining about the retroactive application of detailed operation guidelines revised in April at this year's PVA. Although it has already officially proposed excluding retroactive application to the NHIS twice, the NHIS' position is firm. Analysts say that such an issue will be a hurdle to settle the negoti
- Policy
- Negotiations for Pfizer Lorviqua have not been completed
- by Lee, Tak-Sun Jul 22, 2022 05:52am
- It was found that Lorviqua' a third-generation non-small cell lung cancer treatment that inhibits ALK (anaplastic lymphoma kinase), failed just before being listed. The HIRA announced the establishment of a standard next month, but the NHIS negotiations were not completed, leading to the deletion again. According to the industry on the 19th
- Policy
- “Pharma companies cannot conduct online product briefings"
- by Kim, Jung-Ju Jul 21, 2022 06:04am
- “Online product briefing sessions by pharmaceutical companies are clearly illegal, but we cannot directly warn the pharmaceutical industry by pressing charges or requesting investigations at the moment." With the prohibition temporarily lifted on the pharmaceutical and medical device companies’ support of online academic conferences,
- Policy
- Companies receive mixed reimb results in urothelial cancer
- by Lee, Tak-Sun Jul 20, 2022 05:49am
- The changes made in the reimbursement standards for urothelial carcinoma brought joy or sadness to affected companies. A new reimbursement standard for urothelial carcinoma has been created for MSD’s ‘Keytruda inj (pembrolizumab),’ while the reimbursement standard for Roche’s ‘Tecentriq inj (atezolizumab)' has been removed from the li
- Policy
- The age group for SKYCovione was expanded
- by Lee, Jeong-Hwan Jul 20, 2022 05:49am
- SK Bioscience has expanded the conditions for clinical trials for cross-administration of booster shots (additional inoculations) of the nation's first COVID-19 vaccine SKYCovione (GBP510) to those aged 50 or older. This is due to the recent diversification of mutations and the re-proliferation of COVID-19. As a result, the company is expecte
- Policy
- Lipilouzet, which is more expensive than Atozet
- by Lee, Tak-Sun Jul 20, 2022 05:49am
- Chong Kun Dang is establishing a clear position in the market for the hyperlipidemia complex Atorvastatin-Ezetimibe complex. This is because MSD's Atozet, the original drug, has been jointly sold since 2016, and there is even a certain insurance called Lipilouzet. Lipilouzet has a higher upper limit than Atozet. According to an industry on th
- Policy
- To halve the death rate from COVID-19
- by Lee, Jeong-Hwan Jul 18, 2022 06:06am
- As the domestic quarantine authorities announced their plan to review and promote the purchase of Sabizabulin, a new oral treatment for severe patients in preparation for the COVID-19 re-pandemic, attention is being paid to the treatment. Sabizabulin, developed by U.S. pharmaceutical company Veru, is the first serious oral treatment for CO
- Policy
- Abbott has filed a suspension of execution with the court
- by Kim, Jung-Ju Jul 18, 2022 06:06am
- Abbott Korea, which has been in a dispute with the Ministry of Health and Welfare, immediately filed an appeal against the administrative court ruling by raising the issue of lowering the additional revaluation of the Rytmonorm SR series. Leo Pharma, which raised the issue together last year, decided to avoid legal confrontation with the gove
